Meta-analysis of once-daily and twice-daily lopinavir/ritonavir combined with NRTIs in HIV-1-infected, antiretroviral-naive patients

By van Wyk Jean   Qaqish Roula   Hollar Kimberly   White Kelly   D’’Amico Ronald   Norton Michael   Chiu Yi-Lin   King Martin  

Future Virology, Vol. 7, Iss. 1, 2012-01 ,pp. : 103-113

Future Medicine

Access to resources Recommend Favorite

The once-daily lamivudine plus abacavir fixed combination is noninferior to the twice daily regimen of the individual components

By  

Inpharma, Vol. 1, Iss. 1520, 2006-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Once daily lamivudine looks promising in HIV-1 infection

By  

Inpharma, Vol. 1, Iss. 1306, 2001-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia

By Jones B.   De Smedt G.   Lemmens P.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 350-350

Elsevier

Access to resources Recommend Favorite

Single‐ and multiple‐dose study to evaluate pharmacokinetics, safety and tolerability in healthy volunteers: A comparison of extended‐release oxycodone with sequestered naltrexone 40 mg twice daily to oxycontin 40 mg twice daily and extended‐release oxycodone with sequestered naltrexone 80 mg once daily

By  

Clinical Pharmacology In Drug Development, Vol. 4, Iss. 5, 2015-09 ,pp. : 361-369

John Wiley & Sons Inc

Access to resources Recommend Favorite